Ciloa
Dedicated to the production of fully native membrane proteins on exosomes.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | €6.5m | Grant | |
| Total Funding | 000k | ||
| EUR | 2016 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| % EBITDA margin | (4 %) |
| Profit | 0000 |
| % profit margin | (54 %) |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Company filings or news article
Related Content
Ciloa is a preclinical biotechnology company that engineers extracellular vesicles (EVs) to create new therapeutics and preventive treatments. The company has developed a proprietary, integrated platform for the production, purification, and qualification of bioengineered EVs, specifically exosomes. This technology allows for the in-vivo customization of exosomes to carry specific membrane proteins, enabling the pursuit of targets that were previously considered undruggable.
The company's primary focus is on developing treatments for metabolic diseases, with a lead candidate based on adiponectin for obesity and type 2 diabetes. Ciloa operates in the biopharmaceutical market, collaborating with other entities to advance its drug development projects. Its business model revolves around leveraging its exosome engineering platform to develop a pipeline of drug candidates, funded in part by government grants, such as the France 2030 innovation fund.
Keywords: extracellular vesicles, exosomes, biotherapeutics, drug development, metabolic disease, obesity, type 2 diabetes, protein engineering, biomanufacturing, preclinical.